Third, the FXR agonist obeticholic acid has been demonstrated to have promising clinical results in the treatment of liver disorders such as primary biliary cirrhosis, primary sclerosing cholangitis, and nonalcoholic steatohepatitis [40]. Here, NR1H4 is linked to sclerosing cholangitis.